网页第一三共肿瘤临床管线的五大adc 药物之一。ds-6000 采用第一三共专有的 dxd-adc 技术设计，由人源化抗cdh6 igg1 单克隆抗体与拓扑异构酶i 抑制剂 有效载荷（喜树碱类衍生物dxd），通过可裂解四肽连接子组合而成。
第一三共/默沙东CDH6靶向ADC新药DS-6000a获批临床，针对卵巢 …
网页DS-6000a （Raludotatug deruxtecan， R-DXd）是一款靶向 CDH6 的 ADC 药物，由人源化抗 CDH6 IgG1 单克隆抗体， DXD 作为 payload，四肽的可裂解连接子组成， DAR 值约为 8。 2023 年 10 月，默沙东（MSD）与第一三共达成一项高达 220 亿美元的合作共同开发后者的三个 ADC， DS-6000a 就是其中之一。 CDH6 （钙粘蛋白 -6 或 K- 钙粘蛋白）是针对多种恶性实体肿瘤的高潜力 ADC 靶点。 CDH6 在卵巢癌和肾癌中高表达，数据还表明， …
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 ...
网页2021年2月3日 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi Sankyo oncology pipeline to enter clinical development. DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via …
DS-6000 Suggests Early Clinical Activity in Patients with Advanced ...
网页2022年6月7日 · Initial dose escalation results from first-in-human phase 1 trial of DS-6000, Daiichi Sankyo’s fifth DXd ADC in clinical development, featured in oral presentation at ASCO Dose expansion phase currently enrolling …
网页2022年6月7日 · DS-6000 is an investigational potential first- in-class CDH6 directed ADC and one of five ADCs in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS -6000 is comprised of a humanized anti -CDH6 IgG1 monoclonal antibody attached to a
Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug …
网页2024年3月4日 · Here, we generated raludotatug deruxtecan (R-DXd; DS-6000), a novel CDH6-targeting antibody–drug conjugate with a potent DNA topoisomerase I inhibitor, and evaluated its properties, pharmacologic activities, and safety profile.
Phase I, two-part, multicenter, first-in-human (FIH) study of DS …
网页2022年6月2日 · DS-6000a is an antibody-drug conjugate, comprised of an humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I (TOP1) inhibitor payload via a cleavable linker. DS-6000a specifically binds to CDH6 on the surface of tumor cells and is internalized upon binding. The payload is then released, resulting in target cell apoptosis.
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 …
网页2021年2月2日 · DS-6000 is a potential first-in-class CDH6 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi...
第一三共CDH6 ADC药物DS-6000a首次临床申请获CDE受理！
网页DS-6000a （Raludotatug deruxtecan，R-DXd）是一款靶向CDH6的ADC药物， 由人源化抗CDH6 IgG1单克隆抗体，DXD作为payload，四肽的可裂解连接子组成，DAR值约为8。 钙粘蛋白6
Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC …
网页2021年2月23日 · DS-6000 is a first-in-class agent that is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker....